{"id":95560,"date":"2023-09-18T09:37:00","date_gmt":"2023-09-18T02:37:00","guid":{"rendered":"https:\/\/www.xinwengao.com\/cn\/pr\/2023091809370095560"},"modified":"2023-09-18T17:39:53","modified_gmt":"2023-09-18T09:39:53","slug":"%e5%8b%83%e6%9e%97%e6%a0%bc%e6%ae%b7%e6%a0%bc%e7%bf%b0%e4%b8%ba%e4%b8%ad%e5%9b%bd%e8%b6%85%e9%87%8d%e6%88%96%e8%82%a5%e8%83%96%e4%ba%ba%e7%be%a4%e8%ae%be%e8%ae%a1%e7%9a%84iii%e6%9c%9f%e4%b8%b4","status":"publish","type":"post","link":"https:\/\/www.xinwengao.com\/cn\/pr\/2023091809370095560","title":{"rendered":"\u52c3\u6797\u683c\u6bb7\u683c\u7ff0\u4e3a\u4e2d\u56fd\u8d85\u91cd\u6216\u80a5\u80d6\u4eba\u7fa4\u8bbe\u8ba1\u7684III\u671f\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u9012\u4ea4"},"content":{"rendered":"<p><p><span id=\"spanHghlt70b9\"><b>\u533b\u5b66\u5ba1\u6279\u53f7\uff1a<\/b><b>MPR-CN-101785<\/b><\/span><\/p>\n<ul type=\"disc\">\n<li>Survodutide\u662f\u52c3\u6797\u683c\u6bb7\u683c\u7ff0\u5fc3\u80be\u4ee3\u8c22\u9886\u57df\u7684\u5728\u7814\u836f\u7269\uff0c6\u6708\u4efd\u516c\u5e03\u7684II\u671f\u6570\u636e\u8868\u73b0\u79ef\u6781\uff0c\u516c\u53f8\u5168\u9762\u63a8\u8fdbIII\u671f\u4e34\u5e8a\u8bd5\u9a8c<\/li>\n<li>8\u6708\uff0c\u4e2d\u56fd\u4e0e\u5168\u7403\u540c\u65f6\u9012\u4ea4III\u671f\u56fd\u9645\u591a\u4e2d\u5fc3\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\uff0c\u5c06\u6df1\u5165\u9a8c\u8bc1survodutide\u7684\u7597\u6548\u548c\u5b89\u5168\u6027<\/li>\n<li>9\u6708\uff0c\u4e2d\u56fd\u72ec\u7acb\u8bbe\u8ba1\u7684III\u671f\u591a\u4e2d\u5fc3\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u5c06\u8fdb\u4e00\u6b65\u4ea7\u751fsurvodutide\u5728\u4e2d\u56fd\u8d85\u91cd\u6216\u80a5\u80d6\u4eba\u7fa4\u4e2d\u7597\u6548\u548c\u5b89\u5168\u6027\u7684\u5faa\u8bc1\u533b\u5b66\u8bc1\u636e\u3002\u66f4\u591a\u7814\u7a76\u7ec6\u8282\u5c06\u5728\u7814\u7a76\u542f\u52a8\u524d\u516c\u5e03\uff0c\u9884\u8ba1\u57282024\u5e74\u521d\u5f00\u59cb\u5165\u7ec4\u60a3\u8005<\/li>\n<\/ul>\n<p><span class=\"legendSpanClass\">\u4e0a\u6d77<\/span><span class=\"legendSpanClass\">2023\u5e749\u670818\u65e5<\/span> \/\u7f8e\u901a\u793e\/ &#8212; 2023\u5e749\u670818\u65e5\uff0c\u52c3\u6797\u683c\u6bb7\u683c\u7ff0\u4e2d\u56fd\u5411\u56fd\u5bb6\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40\u836f\u54c1\u5ba1\u8bc4\u4e2d\u5fc3\uff08CDE, NMPA\uff09\u6210\u529f\u9012\u4ea4\u9488\u5bf9\u4e2d\u56fd\u8d85\u91cd\u6216\u80a5\u80d6\u4eba\u7fa4\u7684\u591a\u4e2d\u5fc3\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u3002\u8be5\u8bd5\u9a8c\u65e8\u5728\u8fdb\u4e00\u6b65\u63a2\u7d22survodutide\uff08GCGR\/GLP-1R\u53cc\u91cd\u6fc0\u52a8\u5242\uff09\u5728\u4e2d\u56fd\u60a3\u8005\u4e2d\u7684\u7597\u6548\u548c\u5b89\u5168\u6027\u3002\u6b64\u524d\u516c\u5e03\u7684\u5168\u7403\u591a\u4e2d\u5fc3II\u671f\u4e34\u5e8a\u7814\u7a76\u6570\u636e\u8868\u660e\uff0c\u5728\u4e3a\u671f46\u5468\u7684survodutide\u6cbb\u7597\u671f\u540e\uff0c\u60a3\u8005\u4f53\u91cd\u51cf\u8f7b\u53ef\u9ad8\u8fbe19%<sup><span id=\"spanHghlt3845\">[1]<\/span><\/sup>\u3002<\/p>\n<p>\u6839\u636e\u4e16\u754c\u536b\u751f\u7ec4\u7ec7\u7684\u7edf\u8ba1\u6807\u51c6\uff0c\u622a\u81f32016\u5e74\uff0c\u5168\u7403\u8d85\u8fc719\u4ebf\u6210\u5e74\u4eba\u4f53\u91cd\u8d85\u91cd\uff08BMI\u226525 kg\/m<sup>2<\/sup>\uff09<sup><span id=\"spanHghlt0752\">[2]<\/span><\/sup>\uff0c\u5176\u4e2d\u8d85\u8fc76.5\u4ebf\u4eba\u60a3\u6709\u80a5\u80d6\uff08BMI\u226530 kg\/m<sup>2<\/sup>\uff09<sup><span id=\"spanHghltf01d\">[3]<\/span><\/sup>\u3002\u80a5\u80d6\u662f\u6307\u53ef\u80fd\u635f\u5bb3\u5065\u5eb7\u7684\u5f02\u5e38\u6216\u8fc7\u591a\u8eab\u4f53\u8102\u80aa\u84c4\u79ef, \u5c5e\u4e8e\u6162\u6027\u3001\u6613\u590d\u53d1\u3001\u8fdb\u884c\u6027\u75be\u75c5\u72b6\u6001\uff0c\u76ee\u524d\u5df2\u6210\u4e3a\u56fd\u9645\u548c\u56fd\u5185\u90fd\u5341\u5206\u91cd\u89c6\u7684\u516c\u5171\u536b\u751f\u95ee\u9898\u3002<\/p>\n<p>\u4e0d\u540c\u4e8e\u4e16\u536b\u7ec4\u7ec7\u7684\u5b9a\u4e49\uff0c\u4e2d\u56fd\u80a5\u80d6\u95ee\u9898\u5de5\u4f5c\u7ec4\u57fa\u4e8e\u4e2d\u56fd\u60a3\u8005\u7684\u7279\u70b9\uff0c\u5efa\u8bae\u8bbe\u5b9aBMI\u503c24.0kg\/m<sup>2<\/sup>\u4e3a\u8d85\u91cd\u4e34\u754c\u503c\uff0c28.0 kg\/m<sup>2<\/sup>\u4e3a\u80a5\u80d6\u4e34\u754c\u503c\u3002\u300a\u4e2d\u56fd\u5c45\u6c11\u8425\u517b\u4e0e\u6162\u6027\u75c5\u72b6\u51b5\u62a5\u544a\uff082020\u5e74\uff09\u300b\u663e\u793a\uff0c\u6210\u4eba\uff08\u226518\u5c81\uff09\u7684\u8d85\u91cd\u7387\u4e3a34.3%\u3001\u80a5\u80d6\u7387\u4e3a16.4%\uff0c\u8d85\u91cd\/\u80a5\u80d6\u6210\u5e74\u4eba\u5df2\u8fc7\u534a\u3002\u6309\u7167\u7edd\u5bf9\u4eba\u53e3\u6570\u6765\u8ba1\u7b97\uff0c\u6211\u56fd\u76ee\u524d\u5df2\u67096\u4ebf\u4eba\u8d85\u91cd\u548c\u80a5\u80d6\uff0c\u663e\u7136\u8fd9\u4e2a\u6570\u5b57\u5728\u5168\u7403\u6392\u540d\u7b2c\u4e00\u3002\u8d85\u91cd\u548c\u80a5\u80d6\u662f\u590d\u6742\u7684\u6162\u6027\u75be\u75c5\uff0c\u6d89\u53ca\u8102\u80aa\u7684\u5f02\u5e38\u6216\u8fc7\u5ea6\u84c4\u79ef\uff0c\u5bf9\u4e2a\u4eba\u6574\u4f53\u5065\u5eb7\u6784\u6210\u5a01\u80c1\u3002<sup><span id=\"spanHghlt74cb\">[4]<\/span><\/sup><\/p>\n<p>\u52c3\u6797\u683c\u6bb7\u683c\u7ff0\u5927\u4e2d\u534e\u533a\u7814\u53d1\u548c\u533b\u5b66\u9ad8\u7ea7\u526f\u603b\u88c1\u5f20\u7ef4\u535a\u58eb\u8868\u793a\uff0c&quot;\u4ee3\u8c22\u548c\u5fc3\u8840\u7ba1\u3001\u80be\u75c5\u75be\u75c5\u662f\u52c3\u6797\u683c\u6bb7\u683c\u7ff0\u6df1\u8015\u7684\u75be\u75c5\u9886\u57df\u4e4b\u4e00\uff0c\u6211\u4eec\u6df1\u77e5\u8be5\u9886\u57df\u4e2d\u5b58\u5728\u5de8\u5927\u672a\u88ab\u6ee1\u8db3\u7684\u4e34\u5e8a\u9700\u6c42\u3002\u76ee\u524d\u4e2d\u56fd\u4e34\u5e8a\u7814\u53d1\u56e2\u961f\u6b63\u79ef\u6781\u51c6\u5907\u53c2\u4e0e\u5168\u7403\u591a\u4e2d\u5fc3III\u671f\u4e34\u5e8a\u8bd5\u9a8c\u7684\u524d\u671f\u5de5\u4f5c\u3002\u4e0e\u6b64\u540c\u65f6\uff0c\u6211\u4eec\u4e5f\u671f\u5f85\u8be5\u4e2d\u56fd\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u80fd\u591f\u65e9\u65e5\u83b7\u6279\uff0c\u4ea7\u751fsurvodutide\u4e13\u95e8\u9488\u5bf9\u4e2d\u56fd\u8d85\u91cd\u548c\u80a5\u80d6\u60a3\u8005\u7684\u6709\u6548\u6027\u548c\u5b89\u5168\u6027\u7684\u5faa\u8bc1\u533b\u5b66\u8bc1\u636e\u3002&quot;<\/p>\n<p><b>\u5173\u4e8e<\/b><b>Survodutide<\/b><\/p>\n<p>Survodutide \u662f\u4e00\u79cdGCGR\/GLP-1R\u53cc\u91cd\u6fc0\u52a8\u5242\uff0c\u53ef\u540c\u65f6\u6fc0\u6d3b\u80f0\u9ad8\u8840\u7cd6\u7d20\u6837\u80bd-1\uff08 GLP-1 \uff09\u53d7\u4f53\u548c\u80f0\u9ad8\u8840\u7cd6\u7d20\uff08GCG\uff09\u53d7\u4f53\uff0c\u5728\u6291\u5236\u98df\u6b32\u7684\u540c\u65f6\uff0c\u8fd8\u80fd\u63d0\u9ad8\u80fd\u91cf\u6d88\u8017\uff0c\u4ece\u800c\u6cbb\u7597\u80a5\u80d6<sup><span id=\"spanHghlt3d18\">[5]<\/span><\/sup>\u3002\u76ee\u524d\uff0c\u516c\u53f8\u4e5f\u5728\u540c\u671f\u5f00\u5c55\u53e6\u4e00\u9879II\u671f\u7814\u7a76\uff0c\u65e8\u5728\u8bc4\u4f30survodutide\u5bf9\u975e\u9152\u7cbe\u8102\u80aa\u6027\u809d\u708e\uff08NASH\uff09\u548c\u809d\u7ea4\u7ef4\u5316\uff08F1\/F2\/F3\u671f\uff09\u6210\u4eba\u60a3\u8005\uff08\u65e0\u8bba\u662f\u5426\u60a3\u67092\u578b\u7cd6\u5c3f\u75c5\uff09\u7684\u7597\u6548\u3002\u8bd5\u9a8c\u9884\u8ba1\u57282023\u5e74\u7b2c4\u5b63\u5ea6\u5b8c\u6210\u3002<sup><span id=\"spanHghlt22db\">[6]<\/span><\/sup>\u8be5\u7814\u7a76\u5df2\u83b7\u5f97\u7f8e\u56fdFDA\u9488\u5bf9\u5176\u6210\u4ebaNASH\u9002\u5e94\u75c7\u7684\u5feb\u901f\u901a\u9053\u8d44\u683c\u8ba4\u5b9a\u3002<sup><span id=\"spanHghlt269c\">[7]<\/span><\/sup>\u3002Survodutide\u7531\u52c3\u6797\u683c\u6bb7\u683c\u7ff0\u548cZealand Pharma\u8054\u5408\u5f00\u53d1\uff0c\u662f\u52c3\u6797\u683c\u6bb7\u683c\u7ff0\u5728\u5fc3\u80be\u4ee3\u8c22\u75be\u75c5\u9886\u57df\u91cd\u8981\u7684\u5728\u7814\u836f\u7269\u4e4b\u4e00\u3002<\/p>\n<p>&nbsp;<b>\u5173\u4e8e\u52c3\u6797\u683c\u6bb7\u683c\u7ff0\u4e2d\u56fd<\/b><\/p>\n<p>\u52c3\u6797\u683c\u6bb7\u683c\u7ff0\u516c\u53f8\u662f\u5168\u7403\u9886\u5148\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u4e4b\u4e00\u3002\u603b\u90e8\u4f4d\u4e8e\u5fb7\u56fd\u6bb7\u683c\u7ff0\uff0c\u5168\u7403\u8d85\u8fc753,000\u540d\u5458\u5de5\u3002\u4e3a\u4eba\u7c7b\u4e0e\u52a8\u7269\u5f00\u53d1\u5168\u65b0\u3001\u66f4\u597d\u7684\u836f\u7269\u662f\u6211\u4eec\u5de5\u4f5c\u7684\u6838\u5fc3\u3002\u52c3\u6797\u683c\u6bb7\u683c\u7ff0\u4e2d\u56fd\u603b\u90e8\u4f4d\u4e8e\u4e0a\u6d77\uff0c\u76ee\u524d\u5168\u56fd\u8303\u56f4\u5185\u62e5\u6709\u8d85\u8fc73,800\u540d\u5458\u5de5\uff0c\u6838\u5fc3\u4e1a\u52a1\u5305\u62ec\uff1a\u4eba\u7528\u836f\u54c1\u3001\u52a8\u7269\u4fdd\u5065\u548c\u751f\u7269\u5236\u836f\u5408\u540c\u751f\u4ea7\u3002\u8fd1\u5e74\u6765\uff0c\u52c3\u6797\u683c\u6bb7\u683c\u7ff0\u5728\u4e2d\u56fd\u6536\u83b7\u957f\u8db3\u53d1\u5c55\uff0c\u5e76\u8fde\u7eed\u5341\u5e74\u8363\u83b7&quot;\u4e2d\u56fd\u6770\u51fa\u96c7\u4e3b&quot;\u8ba4\u8bc1\u3002\u4e2d\u56fd\u662f\u52c3\u6797\u683c\u6bb7\u683c\u7ff0\u7684\u91cd\u70b9\u5e02\u573a\u548c\u521b\u65b0\u9ad8\u5730\u4e4b\u4e00\uff0c\u516c\u53f8\u5c06\u4e2d\u56fd\u60a3\u8005\u7684\u9700\u6c42\u7eb3\u5165\u5168\u7403\u7814\u53d1\u7b56\u7565\uff0c\u81f4\u529b\u4e8e\u628a\u66f4\u591a\u66f4\u597d\u7684\u521b\u65b0\u4ea7\u54c1\u66f4\u65e9\u5730\u5e26\u7ed9\u4e2d\u56fd\u7684\u60a3\u8005\uff0c\u52a9\u529b\u4e2d\u56fd\u5065\u5eb7\u4ea7\u4e1a\u7684\u9ad8\u8d28\u91cf\u53d1\u5c55\uff0c\u5168\u9762\u6539\u5584\u4eba\u4e0e\u52a8\u7269\u7684\u5065\u5eb7\u3002\u66f4\u591a\u8be6\u60c5\uff0c\u8bf7\u8bbf\u95ee\uff1a<a href=\"http:\/\/www.boehringer-ingelheim.com\/\" target=\"_blank\" rel=\"nofollow noopener\">www.boehringer-ingelheim.com<\/a>,&nbsp; <a href=\"http:\/\/www.boehringer-ingelheim.cn\/\" target=\"_blank\" rel=\"nofollow noopener\">www.boehringer-ingelheim.cn<\/a><\/p>\n<div>\n<table border=\"0\" cellspacing=\"0\" cellpadding=\"1\" class=\"prnbcc\">\n<tbody>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>\u53c2\u8003\u8d44\u6599<\/b><\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">[1] Data shows nearly 19% weight loss in people with overweight or obesity in Boehringer Ingelheim and Zealand Pharma Phase II trial with survodutide (BI 456906). Available at https:\/\/www.boehringer-ingelheim.com\/human-health\/metabolic-diseases\/obesity\/phase-ii-clinical-trial-weight-loss-results.<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">[2] World Health Organization. Obesity and Overweight. Available at: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight. Accessed June 2023.<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">[3] World Heart Federation. Obesity. 2015. Available at: https:\/\/world-heart-federation.org\/what-we-do\/obesity\/#:~:text=Global%20estimates%20suggest%20that%20almost,overweight%20or%20obesity%20by%202025 . Accessed June 2023.<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">[4] Bray GA et al. Obesity: A chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obes Rev 2017;18:715\u2013723.<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">[5] T. Zimmerman et al. BI 456906: Discovery and preclinical pharmacology of a novel GCGR\/GLP-1R dual agonist with robust anti-obesity efficacy. Molecular Metabolism. 2022;66:101633.<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">[6] ClinicalTrials.gov: A Study to Test Safety and Efficacy of BI456906 in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3). Available at &nbsp;https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04771273https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04771273 Accessed June 2023.<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">[7] Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH. https:\/\/www.boehringer-ingelheim.com\/us\/press-release\/boehringer-ingelheim-and-zealand-pharma-receive-fda-fast-track-designation. Accessed June 2023.<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u533b\u5b66\u5ba1\u6279\u53f7\uff1aMPR-CN-101785 Survodutide\u662f\u52c3\u6797\u683c\u6bb7\u683c\u7ff0\u5fc3\u80be\u4ee3\u8c22\u9886\u57df\u7684\u5728\u7814\u836f\u7269\uff0c6\u6708\u4efd\u516c\u5e03\u7684II\u671f\u6570\u636e\u8868\u73b0\u79ef\u6781\uff0c\u516c\u53f8\u5168\u9762\u63a8\u8fdbIII\u671f\u4e34\u5e8a\u8bd5\u9a8c 8\u6708\uff0c\u4e2d\u56fd\u4e0e\u5168\u7403\u540c\u65f6\u9012\u4ea4III\u671f\u56fd\u9645\u591a\u4e2d\u5fc3\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\uff0c\u5c06\u6df1\u5165\u9a8c\u8bc1survodutide\u7684\u7597\u6548\u548c\u5b89\u5168\u6027 9\u6708\uff0c\u4e2d\u56fd\u72ec\u7acb\u8bbe\u8ba1\u7684III\u671f\u591a\u4e2d\u5fc3\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u5c06\u8fdb\u4e00\u6b65\u4ea7\u751fsurvodutide\u5728\u4e2d\u56fd\u8d85\u91cd\u6216\u80a5\u80d6\u4eba\u7fa4\u4e2d\u7597\u6548\u548c\u5b89\u5168\u6027\u7684\u5faa\u8bc1\u533b\u5b66\u8bc1\u636e\u3002\u66f4\u591a\u7814\u7a76\u7ec6\u8282\u5c06\u5728\u7814\u7a76\u542f\u52a8\u524d\u516c\u5e03\uff0c\u9884\u8ba1\u57282024\u5e74\u521d\u5f00\u59cb\u5165\u7ec4\u60a3\u8005 \u4e0a\u6d772023\u5e749\u670818\u65e5 \/\u7f8e\u901a\u793e\/ &#8212; 2023\u5e749\u670818\u65e5\uff0c\u52c3\u6797\u683c\u6bb7\u683c\u7ff0\u4e2d\u56fd\u5411\u56fd\u5bb6\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40\u836f\u54c1\u5ba1\u8bc4\u4e2d\u5fc3\uff08CDE, NMPA\uff09\u6210\u529f\u9012\u4ea4\u9488\u5bf9\u4e2d\u56fd\u8d85\u91cd\u6216\u80a5\u80d6\u4eba\u7fa4\u7684\u591a\u4e2d\u5fc3\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u3002\u8be5\u8bd5\u9a8c\u65e8\u5728\u8fdb\u4e00\u6b65\u63a2\u7d22survodutide\uff08GCGR\/GLP-1R\u53cc\u91cd\u6fc0\u52a8\u5242\uff09\u5728\u4e2d\u56fd\u60a3\u8005\u4e2d\u7684\u7597\u6548\u548c\u5b89\u5168\u6027\u3002\u6b64\u524d\u516c\u5e03\u7684\u5168\u7403\u591a\u4e2d\u5fc3II\u671f\u4e34\u5e8a\u7814\u7a76\u6570\u636e\u8868\u660e\uff0c\u5728\u4e3a\u671f46\u5468\u7684survodutide\u6cbb\u7597\u671f\u540e\uff0c\u60a3\u8005\u4f53\u91cd\u51cf\u8f7b\u53ef\u9ad8\u8fbe19%[1]\u3002 \u6839\u636e\u4e16\u754c\u536b\u751f\u7ec4\u7ec7\u7684\u7edf\u8ba1\u6807\u51c6\uff0c\u622a\u81f32016\u5e74\uff0c\u5168\u7403\u8d85\u8fc719\u4ebf\u6210\u5e74\u4eba\u4f53\u91cd\u8d85\u91cd\uff08BMI\u226525 kg\/m2\uff09[2]\uff0c\u5176\u4e2d\u8d85\u8fc76.5\u4ebf\u4eba\u60a3\u6709\u80a5\u80d6\uff08BMI\u226530 kg\/m2\uff09[3]\u3002\u80a5\u80d6\u662f\u6307\u53ef\u80fd\u635f\u5bb3\u5065\u5eb7\u7684\u5f02\u5e38\u6216\u8fc7\u591a\u8eab\u4f53\u8102\u80aa\u84c4\u79ef, \u5c5e\u4e8e\u6162\u6027\u3001\u6613\u590d\u53d1\u3001\u8fdb\u884c\u6027\u75be\u75c5\u72b6\u6001\uff0c\u76ee\u524d\u5df2\u6210\u4e3a\u56fd\u9645\u548c\u56fd\u5185\u90fd\u5341\u5206\u91cd\u89c6\u7684\u516c\u5171\u536b\u751f\u95ee\u9898\u3002 \u4e0d\u540c\u4e8e\u4e16\u536b\u7ec4\u7ec7\u7684\u5b9a\u4e49\uff0c\u4e2d\u56fd\u80a5\u80d6\u95ee\u9898\u5de5\u4f5c\u7ec4\u57fa\u4e8e\u4e2d\u56fd\u60a3\u8005\u7684\u7279\u70b9\uff0c\u5efa\u8bae\u8bbe\u5b9aBMI\u503c24.0kg\/m2\u4e3a\u8d85\u91cd\u4e34\u754c\u503c\uff0c28.0 kg\/m2\u4e3a\u80a5\u80d6\u4e34\u754c\u503c\u3002\u300a\u4e2d\u56fd\u5c45\u6c11\u8425\u517b\u4e0e\u6162\u6027\u75c5\u72b6\u51b5\u62a5\u544a\uff082020\u5e74\uff09\u300b\u663e\u793a\uff0c\u6210\u4eba\uff08\u226518\u5c81\uff09\u7684\u8d85\u91cd\u7387\u4e3a34.3%\u3001\u80a5\u80d6\u7387\u4e3a16.4%\uff0c\u8d85\u91cd\/\u80a5\u80d6\u6210\u5e74\u4eba\u5df2\u8fc7\u534a\u3002\u6309\u7167\u7edd\u5bf9\u4eba\u53e3\u6570\u6765\u8ba1\u7b97\uff0c\u6211\u56fd\u76ee\u524d\u5df2\u67096\u4ebf\u4eba\u8d85\u91cd\u548c\u80a5\u80d6\uff0c\u663e\u7136\u8fd9\u4e2a\u6570\u5b57\u5728\u5168\u7403\u6392\u540d\u7b2c\u4e00\u3002\u8d85\u91cd\u548c\u80a5\u80d6\u662f\u590d\u6742\u7684\u6162\u6027\u75be\u75c5\uff0c\u6d89\u53ca\u8102\u80aa\u7684\u5f02\u5e38\u6216\u8fc7\u5ea6\u84c4\u79ef\uff0c\u5bf9\u4e2a\u4eba\u6574\u4f53\u5065\u5eb7\u6784\u6210\u5a01\u80c1\u3002[4] \u52c3\u6797\u683c\u6bb7\u683c\u7ff0\u5927\u4e2d\u534e\u533a\u7814\u53d1\u548c\u533b\u5b66\u9ad8\u7ea7\u526f\u603b\u88c1\u5f20\u7ef4\u535a\u58eb\u8868\u793a\uff0c&quot;\u4ee3\u8c22\u548c\u5fc3\u8840\u7ba1\u3001\u80be\u75c5\u75be\u75c5\u662f\u52c3\u6797\u683c\u6bb7\u683c\u7ff0\u6df1\u8015\u7684\u75be\u75c5\u9886\u57df\u4e4b\u4e00\uff0c\u6211\u4eec\u6df1\u77e5\u8be5\u9886\u57df\u4e2d\u5b58\u5728\u5de8\u5927\u672a\u88ab\u6ee1\u8db3\u7684\u4e34\u5e8a\u9700\u6c42\u3002\u76ee\u524d\u4e2d\u56fd\u4e34\u5e8a\u7814\u53d1\u56e2\u961f\u6b63\u79ef\u6781\u51c6\u5907\u53c2\u4e0e\u5168\u7403\u591a\u4e2d\u5fc3III\u671f\u4e34\u5e8a\u8bd5\u9a8c\u7684\u524d\u671f\u5de5\u4f5c\u3002\u4e0e\u6b64\u540c\u65f6\uff0c\u6211\u4eec\u4e5f\u671f\u5f85\u8be5\u4e2d\u56fd\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u80fd\u591f\u65e9\u65e5\u83b7\u6279\uff0c\u4ea7\u751fsurvodutide\u4e13\u95e8\u9488\u5bf9\u4e2d\u56fd\u8d85\u91cd\u548c\u80a5\u80d6\u60a3\u8005\u7684\u6709\u6548\u6027\u548c\u5b89\u5168\u6027\u7684\u5faa\u8bc1\u533b\u5b66\u8bc1\u636e\u3002&quot; \u5173\u4e8eSurvodutide Survodutide \u662f\u4e00\u79cdGCGR\/GLP-1R\u53cc\u91cd\u6fc0\u52a8\u5242\uff0c\u53ef\u540c\u65f6\u6fc0\u6d3b\u80f0\u9ad8\u8840\u7cd6\u7d20\u6837\u80bd-1\uff08 GLP-1 \uff09\u53d7\u4f53\u548c\u80f0\u9ad8\u8840\u7cd6\u7d20\uff08GCG\uff09\u53d7\u4f53\uff0c\u5728\u6291\u5236\u98df\u6b32\u7684\u540c\u65f6\uff0c\u8fd8\u80fd\u63d0\u9ad8\u80fd\u91cf\u6d88\u8017\uff0c\u4ece\u800c\u6cbb\u7597\u80a5\u80d6[5]\u3002\u76ee\u524d\uff0c\u516c\u53f8\u4e5f\u5728\u540c\u671f\u5f00\u5c55\u53e6\u4e00\u9879II\u671f\u7814\u7a76\uff0c\u65e8\u5728\u8bc4\u4f30survodutide\u5bf9\u975e\u9152\u7cbe\u8102\u80aa\u6027\u809d\u708e\uff08NASH\uff09\u548c\u809d\u7ea4\u7ef4\u5316\uff08F1\/F2\/F3\u671f\uff09\u6210\u4eba\u60a3\u8005\uff08\u65e0\u8bba\u662f\u5426\u60a3\u67092\u578b\u7cd6\u5c3f\u75c5\uff09\u7684\u7597\u6548\u3002\u8bd5\u9a8c\u9884\u8ba1\u57282023\u5e74\u7b2c4\u5b63\u5ea6\u5b8c\u6210\u3002[6]\u8be5\u7814\u7a76\u5df2\u83b7\u5f97\u7f8e\u56fdFDA\u9488\u5bf9\u5176\u6210\u4ebaNASH\u9002\u5e94\u75c7\u7684\u5feb\u901f\u901a\u9053\u8d44\u683c\u8ba4\u5b9a\u3002[7]\u3002Survodutide\u7531\u52c3\u6797\u683c\u6bb7\u683c\u7ff0\u548cZealand Pharma\u8054\u5408\u5f00\u53d1\uff0c\u662f\u52c3\u6797\u683c\u6bb7\u683c\u7ff0\u5728\u5fc3\u80be\u4ee3\u8c22\u75be\u75c5\u9886\u57df\u91cd\u8981\u7684\u5728\u7814\u836f\u7269\u4e4b\u4e00\u3002 &nbsp;\u5173\u4e8e\u52c3\u6797\u683c\u6bb7\u683c\u7ff0\u4e2d\u56fd \u52c3\u6797\u683c\u6bb7\u683c\u7ff0\u516c\u53f8\u662f\u5168\u7403\u9886\u5148\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u4e4b\u4e00\u3002\u603b\u90e8\u4f4d\u4e8e\u5fb7\u56fd\u6bb7\u683c\u7ff0\uff0c\u5168\u7403\u8d85\u8fc753,000\u540d\u5458\u5de5\u3002\u4e3a\u4eba\u7c7b\u4e0e\u52a8\u7269\u5f00\u53d1\u5168\u65b0\u3001\u66f4\u597d\u7684\u836f\u7269\u662f\u6211\u4eec\u5de5\u4f5c\u7684\u6838\u5fc3\u3002\u52c3\u6797\u683c\u6bb7\u683c\u7ff0\u4e2d\u56fd\u603b\u90e8\u4f4d\u4e8e\u4e0a\u6d77\uff0c\u76ee\u524d\u5168\u56fd\u8303\u56f4\u5185\u62e5\u6709\u8d85\u8fc73,800\u540d\u5458\u5de5\uff0c\u6838\u5fc3\u4e1a\u52a1\u5305\u62ec\uff1a\u4eba\u7528\u836f\u54c1\u3001\u52a8\u7269\u4fdd\u5065\u548c\u751f\u7269\u5236\u836f\u5408\u540c\u751f\u4ea7\u3002\u8fd1\u5e74\u6765\uff0c\u52c3\u6797\u683c\u6bb7\u683c\u7ff0\u5728\u4e2d\u56fd\u6536\u83b7\u957f\u8db3\u53d1\u5c55\uff0c\u5e76\u8fde\u7eed\u5341\u5e74\u8363\u83b7&quot;\u4e2d\u56fd\u6770\u51fa\u96c7\u4e3b&quot;\u8ba4\u8bc1\u3002\u4e2d\u56fd\u662f\u52c3\u6797\u683c\u6bb7\u683c\u7ff0\u7684\u91cd\u70b9\u5e02\u573a\u548c\u521b\u65b0\u9ad8\u5730\u4e4b\u4e00\uff0c\u516c\u53f8\u5c06\u4e2d\u56fd\u60a3\u8005\u7684\u9700\u6c42\u7eb3\u5165\u5168\u7403\u7814\u53d1\u7b56\u7565\uff0c\u81f4\u529b\u4e8e\u628a\u66f4\u591a\u66f4\u597d\u7684\u521b\u65b0\u4ea7\u54c1\u66f4\u65e9\u5730\u5e26\u7ed9\u4e2d\u56fd\u7684\u60a3\u8005\uff0c\u52a9\u529b\u4e2d\u56fd\u5065\u5eb7\u4ea7\u4e1a\u7684\u9ad8\u8d28\u91cf\u53d1\u5c55\uff0c\u5168\u9762\u6539\u5584\u4eba\u4e0e\u52a8\u7269\u7684\u5065\u5eb7\u3002\u66f4\u591a\u8be6\u60c5\uff0c\u8bf7\u8bbf\u95ee\uff1awww.boehringer-ingelheim.com,&nbsp; www.boehringer-ingelheim.cn \u53c2\u8003\u8d44\u6599 [1] Data shows nearly 19% weight loss in people with overweight or obesity in Boehringer Ingelheim and Zealand Pharma Phase II trial with survodutide (BI 456906). Available at https:\/\/www.boehringer-ingelheim.com\/human-health\/metabolic-diseases\/obesity\/phase-ii-clinical-trial-weight-loss-results.&hellip; <a class=\"read-more\" href=\"https:\/\/www.xinwengao.com\/cn\/pr\/2023091809370095560\">Read More<\/a><\/p>\n","protected":false},"author":556,"featured_media":0,"comment_status":"close","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1965],"tags":[],"class_list":["post-95560","post","type-post","status-publish","format-standard","hentry","category-partnerships"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/95560","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/users\/556"}],"replies":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/comments?post=95560"}],"version-history":[{"count":1,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/95560\/revisions"}],"predecessor-version":[{"id":95561,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/95560\/revisions\/95561"}],"wp:attachment":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/media?parent=95560"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/categories?post=95560"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/tags?post=95560"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}